| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PDLIM1; CLIM1; CLP36; PDZ and LIM domain protein 1; C-terminal LIM domain protein 1; Elfin; LIM domain protein CLP-36 |
| Entrez GeneID | 9124 |
| WB Predicted band size | Calculated MW: 36 kDa; Observed MW: 36 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human PDLIM1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4篇关于PDLIM1抗体的参考文献示例(注：文献为虚拟示例，实际引用需根据真实论文调整)：
---
1. **文献名称**：*PDLIM1 suppresses tumor metastasis through actin cytoskeleton remodeling in colorectal cancer*
**作者**：Zhang Y, et al.
**摘要**：研究利用PDLIM1特异性抗体进行免疫组织化学(IHC)和Western blot分析，发现PDLIM1在结直肠癌中低表达，并通过调控细胞骨架重编程抑制肿瘤转移。抗体染色结果显示，PDLIM1缺失与患者预后不良相关。
2. **文献名称**：*PDLIM1 modulates NF-κB signaling and inflammatory responses in macrophages*
**作者**：Lee S, et al.
**摘要**：通过PDLIM1抗体进行免疫共沉淀(Co-IP)和免疫荧光染色，研究发现PDLIM1通过泛素化降解NF-κB信号通路关键蛋白，负向调控巨噬细胞的炎症反应，为自身免疫疾病提供了潜在靶点。
3. **文献名称**：*PDLIM1 as a biomarker for cardiomyocyte hypertrophy: Insights from antibody-based assays*
**作者**：Wang X, et al.
**摘要**：利用PDLIM1单克隆抗体在心肌细胞中检测到其在压力负荷诱导的心肌肥厚中异常表达，并通过染色质免疫沉淀(ChIP)实验揭示其转录调控机制，提示PDLIM1可能作为心脏疾病的诊断标志物。
4. **文献名称**：*Antibody profiling of PDLIM1 in triple-negative breast cancer progression*
**作者**：Gupta R, et al.
**摘要**：研究通过PDLIM1多克隆抗体对三阴性乳腺癌组织进行免疫组化分析，发现PDLIM1高表达与肿瘤侵袭性降低相关，进一步机制研究表明其通过抑制EMT通路抑制转移。
---
如需真实文献，建议在PubMed或Google Scholar中检索关键词“PDLIM1 antibody”或“PDLIM1 function”，并筛选涉及抗体应用的实验研究(如IHC、Western blot等)。
The PDLIM1 antibody is a crucial tool for studying the Protein PDZ and LIM Domain 1 (PDLIM1), a cytoskeletal-associated protein involved in cellular organization, signal transduction, and transcriptional regulation. PDLIM1. also known as CLP-36 or CLIM1. contains a PDZ domain that mediates protein-protein interactions and a LIM domain that influences subcellular localization and functional diversity. It plays roles in actin cytoskeleton remodeling, cell adhesion, and apoptosis by interacting with regulators like α-actinin and PKCε. Dysregulation of PDLIM1 is linked to cancer, inflammation, and cardiovascular diseases, where it may act as a tumor suppressor or context-dependent oncogene.
Antibodies targeting PDLIM1 enable researchers to detect its expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These tools are essential for elucidating PDLIM1's role in disease mechanisms, such as modulating NF-κB signaling in inflammation or suppressing metastatic pathways in cancers. Commercial PDLIM1 antibodies vary in host species, clonality, and epitope specificity, requiring validation for experimental reproducibility. Recent studies highlight its potential as a biomarker or therapeutic target, emphasizing the antibody's importance in both basic research and clinical applications.
×
